Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus

Kevin C. Maki¹, Leslie L. Curry², James M. McKenney³, Mildred V. Farmer⁴, Matthew S. Reeves¹, Mary R. Dicklin¹, John E. Gerich⁵, Bernard Zinman⁶: ¹Provident Clinical Research, Bloomington, IN, ²Cargill, Inc., Wayzata, MN, ³National Clinical Research, Richmond, VA, ⁴Meridien Research, St. Petersburg, FL, ⁵University of Rochester, Rochester, NY, ⁶University of Toronto, Toronto, Ontario

Steviol glycosides, predominantly stevioside and rebaudioside A, extracted from the plant Stevia rebaudiana Bertoni, are used in several countries as food sweetening agents. This randomized, double-blind, placebo-controlled crossover trial examined the glycemic and blood pressure responses during meal tolerance tests to rebaudioside A consumed at three doses (500 mg, 750 mg, and 1000 mg) by men and women with normal glucose tolerance (n=45) or type 2 diabetes mellitus (n=48). Incremental areas under the concentration curves (pre-meal to 240 min) for glucose, insulin, C-peptide, and glucagon did not differ significantly for any dose of rebaudioside A tested vs. placebo or for all rebaudioside A doses combined vs. placebo. There were no significant differences between placebo and rebaudioside A in the effects on postprandial systolic or diastolic blood pressures. Rebaudioside A was well tolerated at all doses. These results suggest that acute consumption of up to 1000 mg of rebaudioside A has no clinically important acute effects on glucose homeostasis or blood pressure among individuals with normal glucose tolerance or type 2 diabetes mellitus.